MedGenome, the leading genetic diagnostics, research, and data company in South Asia, announced today a $50 million investment led by Novo Holdings, an international leader in life science investing.To date, MedGenome has administered more than 300,000 complex genetic tests and served over 200,000 patients. The Company obtains samples from nearly 4,000 hospitals and 10,000 physicians across the globe. Novo’s investment will strengthen MedGenome’s scale beyond India and South Asia into Africa and the Middle East and democratize access to genetic testing and personal healthcare across emerging markets. MedGenome is a co-founding member of the GenomeAsia 100K Project and has built the largest database of South Asian genetic variants―its continued expansion will contribute to the most comprehensive genomic dataset in the world.
MedGenome genetic testing provides insights into complex, noncommunicable diseases to aid in the drug discovery and clinical trials for treatment in the areas of oncology, diabetes, ophthalmology, cardiology, and other rare diseases.
This latest round of funding will be used to broaden MedGenome’s product offering and improve the reach of its key diagnostic services, including reproductive and oncology services, as well as the enhancement of MedGenome’s bioinformatics and SaaS offerings.
“The success that the MedGenome team has achieved over the last decade is extraordinary,” said Amit Kakar at Novo Holdings. “MedGenome’s mission to transform the future of personalized healthcare―one that is affordable, inclusive, and equitable―is a perfect fit with Novo’s investment strategy and broader portfolio.”
“The MedGenome team has built a model of accessibility across South Asia that delivers cutting-edge diagnostic tests, at the same global standard of quality as other market leaders, and at a fraction of the cost,” said Mahesh Pratapneni, Group CEO of MedGenome. “We’re thrilled to have the support of the leader in international life sciences investing behind us as we expand into new global markets and scale access to affordable and life-changing testing.”
“MedGenome is leading the cultural shift of healthcare, taking it from one of generalization to a model that prioritizes precision medicine,” said Dr. Felix Olale, Chairman of MedGenome’s Board of Directors, and Global Co-Lead for Healthcare Investments at LeapFrog Investments. “Breakthroughs and discovery are only as successful as the data on which they’re based, and MedGenome’s mission to expand the global genomic dataset to aid in the development of more inclusive and equitable research & drug discovery is not only inspiring, but critical to the future of global healthcare.”
The investment will give Novo Holdings a significant minority stake in MedGenome. LeapFrog Investments, which led a $55 million investment round in MedGenome in April 2020, will be adding to its investment alongside Novo, as well as existing investor, Sofina.
Experion Technologies, a global IT solutions company enabling enterprises with future-ready digital solutions, announced that it has been listed in the annual Inc. 5000 list as one of the fastest-growing companies in America for the fifth year in a row. The Inc. 5000 list is one of the most prestigious rankings of the fastest-growing private companies in the US. The list represents the most successful companies within the American economy’s most dynamic segment – its independent businesses.
Experion Technologies has climbed up by nearly 100 places since 2021, as a result of a 294% revenue growth that speaks volumes about the company’s continued commitment to being one of the most trusted and results-oriented names in the Product Engineering and Digital Transformation space.
In the past year alone, Experion Technologies has shown fierce determination to scale and grow to be a globally recognised brand. The company’s employee strength grew over 70% while adding several Fortune 500 companies to its clientele across America, Asia, Australia, and Europe. In addition, Experion has won a number of industry-acknowledgements in the past year including Frost & Sullivan’s 2022 Global Customer Value Leadership Award, Great Place to Work® Certification, recognition by The Economic Times as one of the most Promising Brand for 2021, and being featured by the Everest Group as a Major Contender in the Digital Product Engineering Services PEAK Matrix® Assessment 2022.
“This honorary achievement demonstrates our consistent growth and the value we deliver, harnessing our product engineering capabilities. This is definitely a step forward to becoming the most trusted partner for our customers.” says Binu Jacob, MD & CEO of Experion Technologies. “It’s our fifth-time winning in a row which is an outstanding achievement and one that would not have been possible without our team’s unhindered determination of turning challenges into opportunities.”
The companies on the 2022 Inc. 5000 list have not only been successful, but have also demonstrated resilience amid supply chain woes, labor shortages, and the ongoing impact of COVID-19. Among the top 500, the average median three-year revenue growth rate soared to 2,144 percent. Together, those companies added more than 68,394 jobs over the past three years.
“The accomplishment of building one of the fastest-growing companies in the U.S., in light of recent economic roadblocks, cannot be overstated,” says Scott Omelianuk, editor-in-chief of Inc. “Inc. is thrilled to honor the companies that have established themselves through innovation, hard work, and rising to the challenges of today.”
Telugu super news,India, August 2022: Colgate-Palmolive (India) Ltd. (“Colgate India”) today, released its first annual Environmental, Social and Governance (ESG) report. Colgate India introduced their 2025 Sustainability and Social Impact Strategy that guides their approach on ESG through three focused and well-defined pillars of S-MIL-E: Driving Social Impact, Helping Millions of Homes and Preserving our Environment.
These key ambitions are supported by actionable targets, which are designed to manage both risks and opportunities for business and to bring brand purpose to life.
Commenting on the ESG report, Mukul Deoras, Chairman, Colgate-Palmolive (India) Limited said, “Colgate India’s ESG report provides us with an opportunity to share the progress we have achieved in this continued journey and communicate our ambitions and actions to our key stakeholders. It is inspiring to see people making conscious and responsible choices for the environment and the society at large. We are proud that our Colgate brand is in more homes than any other, which is why we believe it’s our responsibility to help the people who buy and use our products to live healthier, more sustainable lives.”
Advancing Sustainability
Colgate mapped out measurable steps towards its 2025 Sustainability & Social Impact Strategy, comprising 10 focused actions and accordingly multiple measurable targets for building a more sustainable future.
Help Children, Young people and Communities Thrive: Colgate empowered 10,000+ women from underserved communities in India with Digital & Financial Literacy in FY 2021-22. Also 44,600+ people, mainly women, – benefited from the water programs for communities, i.e., water accessibility, replenishment, augmentation, rainwater harvesting and Water Sanitation and Hygiene (WASH) in water stressed regions.
Design Sustainable Products: Colgate pioneered recyclable toothpaste tubes in Asia with an open-to-share technology for a circular economy. They also launched the first-ever recycled toothbrush named RecyClean and recently introduced the Colgate Keep toothbrush which has a metal handle and uses 80% less plastic. They also use 90% recyclable cartons for toothpastes and toothbrushes.
Eliminate Plastic Waste: Colgate India continues to achieve 100% of plastic waste collection under Extended Producer Responsibility (EPR) every year. 26.55% of Colgate India’s plastic packaging consists of recyclable material, while 16.9% consists of recycled content. The packaging material comprises paper, out of which 99% is recycled and/or certified materials.
Driving Social Impact
Colgate is committed to inspire its people to make a difference. This is ensured by enabling holistic employee well-being and making continuous learning & development a habit
By cultivating a work environment that embraces diversity, fosters equity and drives inclusion, Colgate encourages everyone to be their authentic selves at work
Helping Millions of Homes
Apart from building sustainable products, Colgate holds ‘Cultivating sustainable habits for life’ close to heart. Hence, enabled cause-based campaigns in India such as #EveryDropCounts, Save Water cause, Save Water Mission and #EveryCupCounts, successfully reached over 100 million people
Preserving Our Environment
With focused environment targets at the heart of our business operations, Colgate works towards accelerating action on Climate change with renewable energy such as solar and wind power, not just at their own sites but also at vendor partner sites.
Under sustainable packaging Colgate has been working on recyclable plastic and cartons across the manufacturing process. Similarly, under sustainable sourcing, 100% of new direct material suppliers are screened for environmental and social criteria
Colgate was honored as the first company in India to have received TRUE® Zero Waste Platinum certification in 2019, for all its four manufacturing (100%) sites, from GBCI. The Sanand & Sri City manufacturing sites are LEED® Gold certified as well.
Colgate has continued to lead the oral care category in India for decades, thereby, taking care of healthy smiles all along. As part of its commitment to advance communities’ health and well-being, the Colgate Bright Smiles, Bright Futures’ oral health education initiative has reached more than 170 Mn+ Children and their families since its inception.
We all know that air purifiers are known to improve air quality, but do air purifiers help with allergies? Most people think that the rainy season cleans up the air, but another lesser-known fact is that it also brings along triggers for allergies. Thereby, Muzaffar Izamuddin, Design Manager, Environmental Care at Dyson, educates consumers about high levels of indoor allergens and how certain air purifiers are designed to clean the air in a room by trapping allergens and pushing filtered, clean air back into the space.
What happens to indoor air quality during the monsoon season?
Increased particulate matter, increased allergens: During monsoons, the humidity levels go up and you are surrounded by damp surfaces and exposed to a higher level of indoor pollutants as well which can trigger respiratory allergies. These allergies are common and are known to cause irritation and discomfort. Moreover, the air inside our homes contains indoor air pollutants that are classified as particulate matter (PM), which refers to particles that are found in the air such as pollen fragments, dust mite fragments and dust mite faeces, as well as particles coming from outdoor pollution, like brake dust and vehicle exhaust particles. Many of these particles 2.5 microns in size or larger can be allergens and larger particles, like skin cells, contribute to dust levels in the home. Due to increased humidity, these common allergens grow more in the monsoon season.
Increase in airborne pollen levels: Allergy sufferers often believe that wet weather keeps pollen counts low. This is not always true. Light-to-moderate rainfall has been found to decrease pollen levels as it can directly wash out airborne pollen, but heavy rain can have the opposite effect. A comprehensive review of US meteorological and pollen count data found that less than 10cm of precipitation tended to reduce pollen levels. But more than 10cm had the reverse effect, tending to increase airborne pollen levels.
What could you be allergic to in your house?
If you feel itchy watery eyes, sneezing, stuffy nose, and wheezing are just as bad if not worse, when you are indoors — you might have some of these allergy triggers to blame, which include dust mites, pollen, pet dander, mold, cockroach droppings, dust mites etc.
Some of the best ways to prevent allergy symptoms are:
Avoid spending significant amounts of time outside on high pollen days.
Keep windows and doors shut at home and in your car during high pollen days.
Shower – and have your family do the same – when they come in from outside in order to get rid of allergens they track in from outdoors.
Wash clothing after coming in from outdoors.
Wear a filter mask when doing yard work such as mowing the lawn or raking leaves.
Protect your eyes and nose with masks or glasses while outdoors.
Vacuum your home regularly with a closed system vacuum cleaner.
Launder linens often and freeze stuffed animals that cannot be washed in warm water.
Deep clean carpets and wash floors to reduce dander, dust mites, and other triggers.
Clean the air in your home using an air purifier with HEPA and carbon filters
Wash greenery such as plants before you bring them in from outside so they are free of mold and insects.
How air purifiers help
Whether cleaning the air or cleaning the carpets, machines with fully sealed filtration systems are crucial to managing allergen capture. Dyson air purifiers combine HEPA-13 filters with a sealed filtration system – so the whole machine now achieves HEPA H13 grade. This ensures that 99.95% of particles as small as 0.1 microns, including visible dust particles to hair, pollen, allergens and bacteria are trapped inside the machine
The second layer of activated carbon captures gases like volatile organic compounds and nitrogen dioxide emitted from cleaning products, cooking or from outdoors. Precision 360-degree rubber seals around the filters to ensure proper sealing within the machine, removing the possibility of air bypassing the filter, and leaking pollen or other allergens back into the room
Genesis Foundation today announced the successful implant of Implantable Cardioverter-defibrillators (ICD) on a seventeen-month-old baby boy, Thomas (name changed), who became the youngest child in India to get an ICD implant via an open chest surgery. The support from their CSR partner, Wipro GE Healthcare, a leading global medical technology and digital solutions innovator, provided the family with the required financial assistance and saved the budding little heart. He was operated on July 22 by Dr. Vijayakumar, Director-Centre for Paediatric Congenital Heart Disease at G Kuppuswamy Naidu Memorial Hospital (GKNM Hospital), Coimbatore.
The surgery is one-of-its-kind – since in general cases the ICD device implant is done inside the heart via open heart surgery, but owing to Thomas’ age, the device was placed on his heart. The baby was diagnosed with a congenital heart defect known as Long QT Syndrome, a rare heart defect where an abnormal cardiac rhythm is experienced due to a delay in the electrical impulses triggering the heart to beat. This leads the patient to recurring syncope (loss of consciousness), which can lead to sudden death due to cardiac arrest. In such cases, an Implantable Cardioverter-defibrillator or an ICD device can help regulate the heart’s electrical impulses and stabilize the patient.
“Thomas survived four episodes of syncope before the surgery. He was fortunate enough to survive them all but another one could have been fatal. This baby proved to be a brave little heart to undergo such major surgery and recover at a good pace. Together we have enabled him to live a near-normal life,” said Dr. Vijayakumar, Padiatric Cardiac Surgeon, GKNM Hospital, Coimbatore.
“Every child is precious, and we believe no child should die due to a lack of funds for treatment. At Genesis Foundation we’re always trying to push boundaries when it comes to ensuring support for underprivileged children born with rare heart defects. We are grateful to GKNM hospital and our CSR partner- Wipro GE for supporting us in giving Thomas a healthy and bright future,” said Simran Sagar, Operations Director, Genesis Foundation.
India contributes significantly to the global diabetes epidemic, with the second-highest diabetes population in the world. Prominent studies underline the need of using medical nutrition therapy (MNT) to achieve and maintain glucose levels, lipid, and weight and to prevent cardiovascular risk factors, for all adults with diabetes or prediabetes. Dietary Fiber (DF) is an important component of the overall strategy to achieve MNT goals and is recommended for effective management of diabetes. While numerous studies link DF to managing diabetes, the information available is scattered.
To address this gap, for the first time, Diabetes India brought together a group of twelve eminent diabetologists and two expert dietitians to review and report on the role of high DF in the management of Type 2 Diabetes Management (T2DM). The authors convened to reach a consensus on the final recommendations between August 2021 and December 2021. It is formally published by Elsevier on behalf of ‘Diabetes India’ in the Diabetes & Metabolic Syndrome: Clinical Research & Reviews.
The prevalence of diabetes is estimated to increase from 425 million people in 2017 to 629 million by 2045.Similar trend estimates the increasing burden of a triple burden of pre-diabetes, diabetes, and obesity in India. As per the study, a high fiber diet is vital for people with diabetes and associated conditions. Increasing fiber intake, preferably through food or through a fiber-rich diabetes (FDN) supplement has proven to be beneficial.
Fiber-rich diabetes nutrition (FDN), a new term coined by the experts to create a fiber-specific diabetes nutrition category, has multi-systemic health benefits. The health benefits of high fiber are improvement in blood sugar control, reduction in blood sugar spikes, decrease in hyperinsulinemia, improvement in cholesterol levels, and weight management in T2DM patients.
An ideal diet for diabetes and associated conditions patients would be a high fiber diet with a gradual step-up of fiber intake going up to the recommended 25-40 g/day. Studies have shown that in T2DM patients, increasing the intake of high fiber foods or fiber rich dietary supplements, particularly of the soluble type will help people in managing diabetes and also in people without diabetes.
Dr. V Mohan from Dr. Mohan’s Diabetes Specialities Centre says, “ To manage diabetes, reducing glycemic peaks is a particularly important target in the treatment of the disorder to improve overall treatment outcomes. A high fiber diet is vital to prevent and manage diabetes. Individuals with diabetes need to be advised not only to increase the quantity of fiber but also to include the right type of fiber or soluble fiber in their diet. Soluble fiber has numerous beneficial effects like lowering blood sugar spikes, management of cholesterol levels, enhancing immune function, increasing satiety, promoting weight loss and improving gut health.
Increasing fiber intake, preferably through food or through dietary supplement which is fiber rich is recommended to prevent and manage diabetes.”
Quote from R&D Team, HUL, “The country is experiencing rapid changes in nutritional habits and a shift in dietary patterns to more ‘modern’ diets leading to low intake of fiber and excess consumption of calories, refined carbohydrates, saturated fats, and sugar. This dietary transition and a sedentary lifestyle have significantly contributed to an increase in T2DM and obesity predominantly in urban, but also in rural areas. We strongly believe there was a need to have user-friendly guidance on the role of high fiber in the management of T2DM and associated conditions that can be easily understood and applied by nutritionists, health care professionals, and the general population at large.”
The writing/editorial support is funded by Hindustan Unilever Ltd.
Merck today announced the appointment of Ms Pratima Reddy as the Managing Director for Merck Specialities Pvt. Ltd, the healthcare business of Merck KGaA, Darmstadt in India. Pratima will lead India’s healthcare strategy and operations, effective August 1, 2022, as successor to Anandram Narasimhan, transitioning into a regional role at APAC. In his role, Anand has steered India and the Emerging Frontier Markets organization to a strong marker, beating growth across therapeutic areas.
Before taking over as the Managing Director of India Operations, Pratima was the Regional Franchise Leader (RFL) of the Cardiovascular, Metabolism and Endocrinology (CM&E) franchise in APAC. An active member of the APAC Leadership team, her efforts have ensured that the CM&E franchise continues to grow in the region and continues its market leadership despite market challenges.
An outcome-oriented leader with demonstrated ability to work across cultures, and business areas, she focuses on creating positive impact across the organisation. “I am privileged to be chosen for this role. Today, more than ever, we need to realize and fulfil our responsibility to improve the overall healthcare ecosystem by working towards providing advanced medical care to patients.” said Ms Pratima Reddy, MD, Merck Specialities Pvt. Ltd.
Pratima has an extensive experience of over 17 years, with nine years in the pharmaceutical industry, including varied roles across functions in national and global teams since joining Merck in October 2013. In addition, she headed the Oncology unit in the country, where she led the turnaround of the Oncology business by demonstrating the opportunity to drive strong growth via focused access strategies.
Telugusuper news.com,Hyderabad,July30,2022: India and Princeton, NJ, USA. July 29, 2022 – Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback Pharma LLC (“Slayback”), to acquire rights in Slayback’s Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify® in U.S. Lumify® is an over-the-counter (OTC) eyedrop that can be used to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr. Reddy’s exclusive rights to the product outside the U.S.
Slayback Pharma is the first company to file an ANDA for the private label equivalent for Lumify® with the USFDA under Paragraph IV certification. The ANDA is currently under USFDA review and covers Brimonidine Tartrate Ophthalmic Solution 0.025% in 2.5 ml and 7.5 ml fill volumes.“We are pleased to license this important OTC ophthalmic product for the U.S. market,” says Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s. “This product complements Dr. Reddy’s growing OTC product portfolio in the eyecare category that includes the private label versions of Pataday Once Daily Relief and Pataday® Twice Daily Relief.”
“Slayback is proud to develop this first-to-file ANDA for Lumify, a significant OTC product in the eye redness reliever category, that continues to highlight the R&D capability of the company,” said Ajay Singh, CEO and Founder of Slayback.The value of total addressable market for this product in the U.S. is approximately $130 million for the 52 weeks period ending June 12, 2022.
Telugusupernews.com,Hyderabad, India, July 29, 2022: Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY |NYSE: RDY | NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2022. The information mentioned in this release is on the basis of consolidated financial statements under International Financial Reporting Standards (IFRS).
Commenting on the results, Co-Chairman & MD, G V Prasad said “Our underlying business revenues adjusted for covid products contribution during last year have grown well. The profits were aided by a few non-recurring incomes, offsetting the near term headwinds. We continue to improve the health of our core businesses through productivity improvement and robust product pipelines”. Revenues Gross Margin
Revenue Mix by Segment Segment Q1 FY23 Q1 FY22 YoY Gr %
Q4 FY22 QoQ Gr % (Rs.) (Rs.) (Rs.) Global Generics 44,324 41,113 8 46,118 (4) North America 17,815 17,390 2 19,971 (11) Europe 4,141 3,994 4 4,444 (7) India 13,339 10,600 26 9,689 38 Emerging Markets 9,028 9,129 (1) 12,013 (25) Pharmaceutical Services and Active Ingredients (PSAI) 7,090 7,540 (6) 7,557 (6) Others 740 541 37 693 7 Total 52,154 49,194 6 54,368 (4)
34%
8%
26% 17% 14% 1% Q1 FY23 Sales Mix
North America Europe India Emerging Markets PSAI Others
4
Revenue Analysis Global Generics (GG) Revenues from GG segment at Rs. 44.3 billion: Year-on-year growth of 8% was driven by new product launches across most of our businesses and divestment of a few non-core brands in India, partly offset by price erosion in our generic markets, and higher base due to covid product sales in previous year. Sequential decline of 4% was due to sales decline in North America (incremental competition on key products and price erosion) and Emerging Markets (normalization of channel inventory in Russia). This was partly offset by new product launches. North America Revenues from North America at Rs. 17.8 billion: Year-on-year growth of 2%, driven by launch of new products and favorable forex rates, which was offset by price erosion in some of our key molecules. Sequential decline of 11% was primarily on account of price erosion and decline in volumes for few products due to incremental competition. During this quarter, we launched 7 new products. This includes launch of Ketorolac, OTC Nicotine Lozenges Original, Methylprednisolone Sodium Succinate, Pemetrexed Injection, Posaconazole Tabs and Sorafenib in the US and Pemetrexed Inj. in Canada. We filed three ANDAs during the quarter. As of 30 th June 2022, cumulatively 86 generic filings are pending for approval with the USFDA (83 ANDAs and 3 NDAs under 505(b)(2) route). Out of these 86 pending filings, 44 are Para IVs and we believe 24 have ‘First to File’ status. Europe Revenues from Europe at Rs. 4.1 billion: Year-on-year growth of 4%, driven by launch of new products and scale up of base business, which was partly offset by price erosion in some molecules and adverse forex rates during the quarter. Sequential decline of 7% was primarily on account of price erosion and adverse forex rates, which was partly offset by volume traction in base business. India Revenues from India at Rs. 13.3 billion: Year-on-year growth of 26% was driven by divestment of a few non-core brands, revenue contribution from the products acquired / in-licensed from Novartis, growth in base business and new products contribution. The growth was partially offset due to covid product sales in Q1 FY22 which was not there in the current quarter.
5 Sequential growth of 38% was primarily driven by divestment of a few non-core brands, revenue contribution from the products acquired / in-licensed from Novartis, new products contribution and growth in base business. We launched five new products during the quarter. Emerging Markets Revenues from Emerging Markets at Rs. 9.0 billion. Year-on-year decline of 1% and sequential decline of 25%: Revenues for Russia at Rs. 3.2 billion. Year-on-year decline of 9% is primarily due to channel inventory normalization post stocking up in Q4 FY22, which was partly offset with launch of new products. Sequential decline of 53% was due to higher base in Q4 FY22 from brand divestment income and channel inventory normalization in the current quarter. Revenues from other CIS countries and Romania at Rs. 1.9 billion. Year-on-year growth of 33% driven by volume traction in base business, favorable price benefits in some of our products and launch of new products. Sequential decline of 16% was primarily on account of reduction in volumes. Revenues from Rest of World (RoW) territories at Rs. 3.9 billion. Year-on-year decline of 6% primarily on account of higher base in Q1 FY22 due to covid product sales and price decline in current quarter, partly offset by new product launches. Sequential growth of 36% was largely attributable to volume traction in our base business, price benefits in some of our markets and launch of new products. Pharmaceutical Services and Active Ingredients (PSAI) Revenues from PSAI at Rs. 7.1 billion. Year-on-year and sequential decline of 6% each. Year-on-year decline was primarily on account of higher base in Q1 FY22 with covid product sales, partly offset by new products launched and favorable forex rates. Sequential decline was primarily due to lower volumes of base business, partly offset by new product launches.
6
Income Statement Highlights: Gross profit margin at 49.9%:
Decreased by ~230 bps over previous year and by ~300 bps sequentially, primarily on account of higher commodity prices, adverse leverage on manufacturing overheads, price erosion and forex related impact, which was partially benefited from brand divestment income.
Gross profit margin for GG and PSAI business segments are at 55.0% and 15.7% respectively. Selling, general & administrative (SG&A) expenses at Rs. 15.5 billion, increased by 3% on a year- on-year basis and declined by 1% sequentially. Year-on-year increase was primarily attributable to investments being done towards marketing of some of our key brands, investments in digitalization and annual increments, which was partially offset with lower legal and professional expenses. On sequential basis, the expenses have been largely flat. Research & development (R&D) expenses at Rs. 4.3 billion. As % to revenues – Q1 FY23: 8.3% | Q4 FY22: 8.0% | Q1 FY22: 9.2%. Our focus continues on building a global pipeline of products across our markets. Other operating income at Rs. 6.0 billion compared to Rs. 0.5 billion in Q1 FY22. The increase was mainly on account of recognition of income from settlement agreement, with Indivior Inc., Indivior UK Limited and Aquestive Therapeutics, Inc., resolving all claims between the parties relating to the generic buprenorphine and naloxone sublingual film. Net Finance income at Rs. 2.3 billion compared to Rs. 0.7 billion in Q1 FY22. The increase was primarily on account of foreign exchange gains due to favorable ruble rates. Profit before Tax at Rs. 14.7 billion, increased by 97% year-on-year and increased by 490% sequentially. Profit after Tax at Rs. 11.9 billion. The effective tax rate is 19.0% for the quarter. Diluted earnings per share is at Rs. 71.40. Other Highlights: EBITDA is at Rs. 17.8 billion and the EBITDA margin is 34.1%. Capital expenditure is at Rs. 3.3 billion. Free cash-flow is a net outflow of Rs. 2.3 billion. Net cash surplus for the company is at Rs. 12.8 billion as on June 30, 2022. Consequently, net debt to equity ratio is (0.06).
7 Earnings Call Details (06:30 pm IST, 09:00 am EDT, July 28, 2022) The management of the Company will host an earnings call to discuss the Company’s financial performance and answer any questions from the participants. Conference Joining Information Option 1: Express Join with DiamondPass™ Pre-register with the below link and join without waiting for the operator. https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=3962534&linkSecurityString=119134f0e6 Option 2: Join through below Dial-In Numbers Universal Access Number: +91 22 6280 1219 +91 22 7115 8120
No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call. Play Back: The play back will be available after the earnings call, till August 3 rd , 2022. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback Code is 96436. Transcript: Transcript of the Earnings call will be available on the Company’s
తెలుగు సూపర్ న్యూస్,హైదరాబాద్ ,జూన్ 24,2022జెమినీ ఎడిబుల్స్ అండ్ ఫ్యాట్స్ ఇండియా లిమిటెడ్ ఫ్లాగ్షిప్ బ్రాండ్ ఫ్రీడమ్ రిఫైన్డ్ సన్ఫ్లవర్ ఆయిల్ ఇండియాలో సన్ఫ్లవర్ ఆయిల్ సెగ్మెంట్లో ఈ ఏడాది వాల్యూమ్ సేల్స్ ప్రకారం నంబర్ వన్ బ్రాండ్గా ర్యాంక్ సాధించింది. ఈ సందర్భంగా జెమినీ ఎడిబుల్స్ అండ్ ఫ్యాట్స్ ఇండియా లిమిటెడ్ మేనేజింగ్ డైరెక్టర్ ప్రదీప్ చౌదరి మాట్లాడుతూ సన్ఫ్లవర్ ఆయిల్ కేటగిరీలో 20.5% విలువతో ‘ఫ్రీడమ్’ భారతదేశంలో నంబర్ వన్ బ్రాండ్గా అవతరించినందుకు మేము సంతోషిస్తున్నాం” ఇది మా వినియోగదారు-కేంద్రీకృత విధానం, పటిష్టమైన పంపిణీ నెట్వర్క్, నాణ్యతపై దృష్టి పెట్టడం ఫలితంగా మా బ్రాండ్ ఈ విజయం సొంతం చేసుకుంది. రాబోయే కొద్ది సంవత్సరాలలో సన్ఫ్లవర్ ఆయిల్ వినియోగం ఎక్కువగా ఉన్న తమిళనాడు, కేరళలో ప్రారంభించాలని మేము భావిస్తున్నామని ఆయన పేర్కొన్నారు.
‘భారతదేశంలో ముడి సన్ఫ్లవర్ ఆయిల్ అత్యధిక దిగుమతిదారు’ విభాగంలో ప్లాటినం అవార్డును కైవసం చేసుకుంది. 2018లో The Globoil India ‘Emerging Brand’ అవార్డు ‘ఫ్రీడమ్’ బ్రాండ్కు దక్కింది. ఇండియా టుడే ‘ఇస్పోస్ అర్బన్ కన్స్యూమర్ సెంటిమెంట్ సర్వే 2020’ ప్రకారం ‘ఫ్రీడమ్’ బ్రాండ్ భారతదేశంలోని టాప్ ఫైవ్ వంట నూనె బ్రాండ్లలో ఒకటిగా నిలిచింది.
